Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2011-05-17
2011-05-17
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reexamination Certificate
active
07943130
ABSTRACT:
The present invention includes compositions and methods for the treatment of Th1 and/or Th2 medicated inflammatory diseases, relating to inhibiting CCR5. This is because the present invention demonstrates, for the first time, that expression of IFN-γ, IL-13, and CCR5 mediates and/or is associated with Th1 and/or Th2 inflammatory diseases and that inhibiting CCR5 treats, and even prevents, the diseases. Thus, the Invention relates to the novel discovery that inhibiting CCR5 treats and prevents Th1 and/or Th2 mediated inflammatory disease.
REFERENCES:
patent: 6100087 (2000-08-01), Rossi et al.
patent: 6476028 (2002-11-01), Bondinell et al.
patent: 6528625 (2003-03-01), Wu et al.
patent: 7282568 (2007-10-01), Teeling et al.
patent: 2003/0017979 (2003-01-01), Mack et al.
patent: 2007/0010509 (2007-01-01), Shiota et al.
patent: 1623721 (2006-02-01), None
patent: 1661889 (2006-05-01), None
patent: WO 01/51077 (2001-07-01), None
patent: WO 01/64213 (2001-09-01), None
patent: WO 2004/056809 (2004-07-01), None
Algood et al. CCR5-deficient mice controlMycobacterium tuberculosisinfection despite increased pulmonary lymphocytic infiltration. J. Immunol. 173:3287-3296 (2004).
Cartier et al. Chemokine-induced cell death in CCR5- expressing neuroblastoma cells. J. Neuroimmunol. 145:27-39 (2003).
Fraziano et al. Expression of CCR5 is increased in human monocyte-derived macrophages and alveolar macrophages in the course of in vivo and in vitroMycobacterium tuberculosisinfection. AIDS Res. Hum. Retroviruses. 15:869-74 (1999).
Huffilagle et al. Cutting edge: Role of C-C chemokine receptor 5 in organ-specific and innate immunity toCryptococcus neoformans. J. Immunol. 163:4642-4646 (1999).
Johnston et al. Radiation-induced pulmonary fibrosis: examination of chemokine and chemokine receptor families. Radiat. Res. 157:256-265 (2002).
Katchar et al. Expression of Th1 markers by lung accumulated T cells in pulmonary sarcoidosis. J. Intern. Med. 254:564-571 (2003).
Kunkel et al. Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. Am. J. Pathol. 160:347-355 (2002).
Luckow et al. Reduced intragraft mRNA expression of matrix metalloproteinases Mmp3; Mmp12, Mmp13 and Adam8, and diminished transplant arteriosclerosis in CCR5-deficient mice. Eur. J. Immunol. 34:2568-2578 (2004).
Nissinen et al. CCR3, CCR5, interleukin 4, and interferon- gamma expression on synovial and peripheral T cells and monocytes in patients with rheumatoid arthritis. J. Rheumatol. 30:1928-1934 (2003).
Santucci et al. Expansion of CCR5+ CD4+ T-lymphocytes in the course of active pulmonary tuberculosis. Eur. Respir. J. 24:638-643 (2004).
Wu et al. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med. 186:1373-1381 (1997).
Elias Jack A.
Ma Bing
Morgan & Lewis & Bockius, LLP
Ouspenski Ilia
Yale University
LandOfFree
Methods and compositions relating to CCR5 antagonist,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions relating to CCR5 antagonist,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions relating to CCR5 antagonist,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2703605